Carpenter-coustan compared with national diabetes data group criteria for diagnosing gestational diabetes

Lorie M. Harper; Lisa Mele; Mark B. Landon; Marshall W. Carpenter; Susan M. Ramin; Uma M. Reddy; Brian Casey; Ronald J. Wapner; Michael W. Varner; John M. Thorp; Anthony Sciscione; Patrick Catalano; Margaret Harper; George Saade; Steve N. Caritis; Yoram Sorokin; Alan M. Peaceman; Jorge E. Tolosa

doi:10.1097/AOG.0000000000001383

Carpenter-coustan compared with national diabetes data group criteria for diagnosing gestational diabetes

Lorie M. Harper, Lisa Mele, Mark B. Landon, Marshall W. Carpenter, Susan M. Ramin, Uma M. Reddy, Brian Casey, Ronald J. Wapner, Michael W. Varner, John M. Thorp, Anthony Sciscione, Patrick Catalano, Margaret Harper, George Saade, Steve N. Caritis, Yoram Sorokin, Alan M. Peaceman, Jorge E. Tolosa

Obstetrics and Gynecology

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

OBJECTIVE: Use of Carpenter-Coustan compared with National Diabetes Data Group criteria increases the number of women diagnosed with gestational diabetes mellitus (GDM) by 30-50%, but whether treatment of this milder GDM reduces adverse outcomes is unknown. We explored the effects of the diagnostic criteria used on the benefits of GDM treatment. METHODS: This was a secondary analysis of a randomized trial for treatment of mild GDM diagnosed using Carpenter-Coustan criteria. We evaluated the effect of treatment within two mutually exclusive diagnostic groups: 1) women who met the stricter National Diabetes Data Group as well as Carpenter-Coustan criteria (National Diabetes Data Group), and 2) those diagnosed by Carpenter-Coustan but not meeting National Diabetes Data Group criteria (Carpenter-Coustan only). Maternal outcomes examined were pregnancy-induced hypertension, shoulder dystocia, maternal weight gain, and cesarean delivery. Neonatal outcomes were large for gestational age, macrosomia (greater than 4,000 g), fat mass, small for gestational age, and a composite outcome of perinatal death, birth injury, hypoglycemia, hyperbilirubinemia, and hyperinsulinemia. Analysis of variance or the Breslow-Day test, as appropriate, was used to test for the interaction between diagnostic criteria and GDM treatment on the outcomes of interest. RESULTS: Of 958 patients, 560 (58.5%) met National Diabetes Data Group criteria and 398 (41.5%) met Carpenter-Coustan only. Compared with untreated women, the direction of treatment effect did not differ by diagnostic criteria used and was consistent with the original trial. The P value for interaction between diagnostic criteria and treatment status was not significant for any outcome. CONCLUSION: The overall beneficial treatment effect on pregnancy-induced hypertension, shoulder dystocia, cesarean delivery, and macrosomia was seen in patients diagnosed by the higher National Diabetes Data Group and by the lower thresholds of the Carpenter-Coustan criteria.

Original language	English (US)
Pages (from-to)	893-898
Number of pages	6
Journal	Obstetrics and gynecology
Volume	127
Issue number	5
DOIs	https://doi.org/10.1097/AOG.0000000000001383
State	Published - Apr 4 2016

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1097/AOG.0000000000001383

Cite this

Harper, L. M., Mele, L., Landon, M. B., Carpenter, M. W., Ramin, S. M., Reddy, U. M., Casey, B., Wapner, R. J., Varner, M. W., Thorp, J. M., Sciscione, A., Catalano, P., Harper, M., Saade, G., Caritis, S. N., Sorokin, Y., Peaceman, A. M., & Tolosa, J. E. (2016). Carpenter-coustan compared with national diabetes data group criteria for diagnosing gestational diabetes. Obstetrics and gynecology, 127(5), 893-898. https://doi.org/10.1097/AOG.0000000000001383

Harper, LM, Mele, L, Landon, MB, Carpenter, MW, Ramin, SM, Reddy, UM, Casey, B, Wapner, RJ, Varner, MW, Thorp, JM, Sciscione, A, Catalano, P, Harper, M, Saade, G, Caritis, SN, Sorokin, Y, Peaceman, AM & Tolosa, JE 2016, 'Carpenter-coustan compared with national diabetes data group criteria for diagnosing gestational diabetes', Obstetrics and gynecology, vol. 127, no. 5, pp. 893-898. https://doi.org/10.1097/AOG.0000000000001383

@article{5b5ac760ce8f45718526c34f860ecde2,

title = "Carpenter-coustan compared with national diabetes data group criteria for diagnosing gestational diabetes",

abstract = "OBJECTIVE: Use of Carpenter-Coustan compared with National Diabetes Data Group criteria increases the number of women diagnosed with gestational diabetes mellitus (GDM) by 30-50%, but whether treatment of this milder GDM reduces adverse outcomes is unknown. We explored the effects of the diagnostic criteria used on the benefits of GDM treatment. METHODS: This was a secondary analysis of a randomized trial for treatment of mild GDM diagnosed using Carpenter-Coustan criteria. We evaluated the effect of treatment within two mutually exclusive diagnostic groups: 1) women who met the stricter National Diabetes Data Group as well as Carpenter-Coustan criteria (National Diabetes Data Group), and 2) those diagnosed by Carpenter-Coustan but not meeting National Diabetes Data Group criteria (Carpenter-Coustan only). Maternal outcomes examined were pregnancy-induced hypertension, shoulder dystocia, maternal weight gain, and cesarean delivery. Neonatal outcomes were large for gestational age, macrosomia (greater than 4,000 g), fat mass, small for gestational age, and a composite outcome of perinatal death, birth injury, hypoglycemia, hyperbilirubinemia, and hyperinsulinemia. Analysis of variance or the Breslow-Day test, as appropriate, was used to test for the interaction between diagnostic criteria and GDM treatment on the outcomes of interest. RESULTS: Of 958 patients, 560 (58.5%) met National Diabetes Data Group criteria and 398 (41.5%) met Carpenter-Coustan only. Compared with untreated women, the direction of treatment effect did not differ by diagnostic criteria used and was consistent with the original trial. The P value for interaction between diagnostic criteria and treatment status was not significant for any outcome. CONCLUSION: The overall beneficial treatment effect on pregnancy-induced hypertension, shoulder dystocia, cesarean delivery, and macrosomia was seen in patients diagnosed by the higher National Diabetes Data Group and by the lower thresholds of the Carpenter-Coustan criteria.",

author = "Harper, {Lorie M.} and Lisa Mele and Landon, {Mark B.} and Carpenter, {Marshall W.} and Ramin, {Susan M.} and Reddy, {Uma M.} and Brian Casey and Wapner, {Ronald J.} and Varner, {Michael W.} and Thorp, {John M.} and Anthony Sciscione and Patrick Catalano and Margaret Harper and George Saade and Caritis, {Steve N.} and Yoram Sorokin and Peaceman, {Alan M.} and Tolosa, {Jorge E.}",

year = "2016",

month = apr,

day = "4",

doi = "10.1097/AOG.0000000000001383",

language = "English (US)",

volume = "127",

pages = "893--898",

journal = "Obstetrics and gynecology",

issn = "0029-7844",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Carpenter-coustan compared with national diabetes data group criteria for diagnosing gestational diabetes

AU - Harper, Lorie M.

AU - Mele, Lisa

AU - Landon, Mark B.

AU - Carpenter, Marshall W.

AU - Ramin, Susan M.

AU - Reddy, Uma M.

AU - Casey, Brian

AU - Wapner, Ronald J.

AU - Varner, Michael W.

AU - Thorp, John M.

AU - Sciscione, Anthony

AU - Catalano, Patrick

AU - Harper, Margaret

AU - Saade, George

AU - Caritis, Steve N.

AU - Sorokin, Yoram

AU - Peaceman, Alan M.

AU - Tolosa, Jorge E.

PY - 2016/4/4

Y1 - 2016/4/4

N2 - OBJECTIVE: Use of Carpenter-Coustan compared with National Diabetes Data Group criteria increases the number of women diagnosed with gestational diabetes mellitus (GDM) by 30-50%, but whether treatment of this milder GDM reduces adverse outcomes is unknown. We explored the effects of the diagnostic criteria used on the benefits of GDM treatment. METHODS: This was a secondary analysis of a randomized trial for treatment of mild GDM diagnosed using Carpenter-Coustan criteria. We evaluated the effect of treatment within two mutually exclusive diagnostic groups: 1) women who met the stricter National Diabetes Data Group as well as Carpenter-Coustan criteria (National Diabetes Data Group), and 2) those diagnosed by Carpenter-Coustan but not meeting National Diabetes Data Group criteria (Carpenter-Coustan only). Maternal outcomes examined were pregnancy-induced hypertension, shoulder dystocia, maternal weight gain, and cesarean delivery. Neonatal outcomes were large for gestational age, macrosomia (greater than 4,000 g), fat mass, small for gestational age, and a composite outcome of perinatal death, birth injury, hypoglycemia, hyperbilirubinemia, and hyperinsulinemia. Analysis of variance or the Breslow-Day test, as appropriate, was used to test for the interaction between diagnostic criteria and GDM treatment on the outcomes of interest. RESULTS: Of 958 patients, 560 (58.5%) met National Diabetes Data Group criteria and 398 (41.5%) met Carpenter-Coustan only. Compared with untreated women, the direction of treatment effect did not differ by diagnostic criteria used and was consistent with the original trial. The P value for interaction between diagnostic criteria and treatment status was not significant for any outcome. CONCLUSION: The overall beneficial treatment effect on pregnancy-induced hypertension, shoulder dystocia, cesarean delivery, and macrosomia was seen in patients diagnosed by the higher National Diabetes Data Group and by the lower thresholds of the Carpenter-Coustan criteria.

AB - OBJECTIVE: Use of Carpenter-Coustan compared with National Diabetes Data Group criteria increases the number of women diagnosed with gestational diabetes mellitus (GDM) by 30-50%, but whether treatment of this milder GDM reduces adverse outcomes is unknown. We explored the effects of the diagnostic criteria used on the benefits of GDM treatment. METHODS: This was a secondary analysis of a randomized trial for treatment of mild GDM diagnosed using Carpenter-Coustan criteria. We evaluated the effect of treatment within two mutually exclusive diagnostic groups: 1) women who met the stricter National Diabetes Data Group as well as Carpenter-Coustan criteria (National Diabetes Data Group), and 2) those diagnosed by Carpenter-Coustan but not meeting National Diabetes Data Group criteria (Carpenter-Coustan only). Maternal outcomes examined were pregnancy-induced hypertension, shoulder dystocia, maternal weight gain, and cesarean delivery. Neonatal outcomes were large for gestational age, macrosomia (greater than 4,000 g), fat mass, small for gestational age, and a composite outcome of perinatal death, birth injury, hypoglycemia, hyperbilirubinemia, and hyperinsulinemia. Analysis of variance or the Breslow-Day test, as appropriate, was used to test for the interaction between diagnostic criteria and GDM treatment on the outcomes of interest. RESULTS: Of 958 patients, 560 (58.5%) met National Diabetes Data Group criteria and 398 (41.5%) met Carpenter-Coustan only. Compared with untreated women, the direction of treatment effect did not differ by diagnostic criteria used and was consistent with the original trial. The P value for interaction between diagnostic criteria and treatment status was not significant for any outcome. CONCLUSION: The overall beneficial treatment effect on pregnancy-induced hypertension, shoulder dystocia, cesarean delivery, and macrosomia was seen in patients diagnosed by the higher National Diabetes Data Group and by the lower thresholds of the Carpenter-Coustan criteria.

UR - http://www.scopus.com/inward/record.url?scp=84964077730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964077730&partnerID=8YFLogxK

U2 - 10.1097/AOG.0000000000001383

DO - 10.1097/AOG.0000000000001383

M3 - Article

C2 - 27054932

AN - SCOPUS:84964077730

SN - 0029-7844

VL - 127

SP - 893

EP - 898

JO - Obstetrics and gynecology

JF - Obstetrics and gynecology

IS - 5

ER -

Carpenter-coustan compared with national diabetes data group criteria for diagnosing gestational diabetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this